Search

Aim: To evaluate the efficacy of coronally advanced flap (CAF) versus tunnel technique (TUN) in covering isolated mid‐facial peri‐implant soft tissue dehiscences (PSTDs). Materials and Methods: Twenty‐eight participants presenting with isolated non‐molar implants exhibiting PSTDs were enrolled and randomized to receive either CAF or TUN, both with a connective tissue graft (CTG). The primary outcome of the study was the percentage of mean PSTD coverage at 12 months. Secondary endpoints included the frequency of complete PSTD coverage, changes in keratinized mucosa width (KMW) and horizontal mucosal thickness (MT), as assessed with transgingival probing, 3D optical scanning and ultrasonography, professional aesthetic evaluation and patient‐reported outcome measures (PROMs). Results: At 12 months, the mean PSTD coverage of the CAF and TUN groups was 90.23% and 59.76%, respectively (p =.03). CAF‐treated sites showed a substantially higher frequency of complete PSTD coverage (p =.07), together with significantly greater gain of KMW (p =.01), increase in MT (p =.02), volumetric gain (p <.01) and professional aesthetic outcomes (p =.01). Both interventions showed an improvement in patient‐reported aesthetics and a reduction of the anxiety related to the appearance of the implant compared to baseline, with the CAF group obtaining significantly higher scores (p =.03 for both PROMs). Conclusions: CAF + CTG resulted in superior PSTD coverage outcomes, greater gain in KMW and MT, and better PROMs than TUN + CTG for the treatment of isolated PSTDs (ClinicalTrials.gov NCT03498911). [ABSTRACT FROM AUTHOR]

Aim: To evaluate the efficacy of recombinant human platelet‐derived growth factor (rhPDGF)‐BB combined with a cross‐linked collagen matrix (CCM) for the treatment of multiple adjacent gingival recession type 1 defects (MAGRs) in combination with the coronally advanced flap (CAF). Materials and Methods: Thirty patients were enrolled in this triple‐blind, randomized, placebo‐controlled trial and treated with either CAF + CCM + rhPDGF, or CAF + CCM + saline. The primary outcome was mean root coverage (mRC) at 6 months. Complete root coverage, gain in gingival thickness (GT), keratinized tissue width, volumetric and ultrasonographic changes, and patient‐reported outcome measures were also assessed. Mixed‐modelling regression analyses were used for statistical comparisons. Results: At 6 months, the mRC of the CCM + rhPDGF and CCM alone groups were 88.25% and 77.72%, respectively (p =.02). A significant gain in GT was consistently observed for both treatment arms, and more so for the patients receiving the matrix containing rhPDGF through time (0.51 vs. 0.80 mm, on average, p =.01). The rhPDGF + CCM treated patients presented greater volume gain, higher soft tissue thickness, and a superior aesthetic score. Conclusion: rhPDGF enhances the clinical, volumetric, and aesthetic outcomes of MAGRs above the results achieved with CAF + CCM alone (ClinicalTrials.gov NCT04462237). [ABSTRACT FROM AUTHOR]